로고

INTRODUCTION

MEMBERS

RESEARCH

BOARD

RESEARCH

Pharmaceutical Economics,
Big Data Analysis & Policy Lab

Conference presentations

Total 168건 11 페이지

2017
18

"Prevalence and incidence of aTherosclerotic cardiovascular disease and cardiovascular risk factors in South Korea: a population-based study" Suh HS, Rane PP, Fox KM, Kim HT, Han S, Kim S, Zhao Z, and Qian Y , The 22nd International Society for Pharmacoeconomics and Outcomes Research Annual Meeting Boston, USA. May 2017.
17

"Experiences of treatment-related side effects and supportive care with Korean medicine in women with breast cancer – a focus group study" Han S, Jang B, Hwang DS, and Suh HS , The 22nd International Society for Pharmacoeconomics and Outcomes Research Annual Meeting Boston, USA. May 2017.
16

"Prescription trend and drug adherence of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation" Han S, Jeong HS, Kim HT, and Suh HS , The 22nd International Society for Pharmacoeconomics and Outcomes Research Annual Meeting Boston, USA. May 2017.
15

"Utilization patterns of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation who failed warfarin Therapy" Han S, Jeong HS, Kim HT, and Suh HS , The 22nd International Society for Pharmacoeconomics and Outcomes Research Annual Meeting Boston, USA. May 2017.
14

"A case-control study of The association between antipsychotics and parkinsonism" Kim S and Suh HS , The 2017 Spring International Convention of The Pharmaceutical Society of Korea Osong, Korea. April 2017.
13

"Re: A case-control study of The association between antipsychotics and parkinsonism" Kim S and Suh HS , The 2017 Spring International Convention of The Pharmaceutical Society of Korea Osong, Korea. April 2017.
12

"Treatment-related side effects and work productivity and activity impairment in patients with breast cancer: A cross-sectional survey in Korea" Han S, Jang BH, Hwang DS, and Suh HS , The 2017 Spring International Convention of The Pharmaceutical Society of Korea Osong, Korea. April 2017.
2016
11

"Value of The clinical decision support system for adverse drug event prevention: a cost-effectiveness analysis and cost-benefit analysis" Kim HT, Suh HS, Ah YM, Lee J, Lee JY, and Lee SH , The International Society for Pharmacoeconomics and Outcomes Research 19st Annual European Congress Vienna, Austria. October-November 2016.
10

"Cost-Effectiveness of Drug Therapy Evaluation and Management (DrugTEAM) service in patients with type 2 diabetes mellitus (T2DM): A cost-utility analysis" Kim S, Suh HS, Je NK, Yoon JH, and Lee IH , The 2016 Fall International Convention of the Pharmaceutical Society of Korea Seoul, Korea. October 2016.
9

"Cost effectiveness analysis of medication safety-related clinical decision support system to prevent adverse drug events" Kim HT, Suh HS, Lee JY, Lee JM, Ah YM, and Lee SH , The 2016 Fall International Convention of the Pharmaceutical Society of Korea Seoul, Korea. October 2016.
8

"Cost benefit analysis for the clinical decision support system to prevent adverse drug events" Kim HT, Suh HS, Lee JY, Lee JM, Ah YM, and Lee SH , The 2016 Fall International Convention of the Pharmaceutical Society of Korea. Seoul Korea. October 2016.
7

"Factors associated with primary nonadherence in patients with chronic disease: analysis based on 2013 Korea Health Panel" Han S and Suh HS , The 2016 Fall International Convention of the Pharmaceutical Society of Korea. Seoul Korea. October 2016.
6

"Utilization patterns and compliance of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation who failed warfarin therapy: a 2014 national healthcare claims database…" Jeong HS, Kim HT, Suh HS , The 2016 Fall International Convention of the Pharmaceutical Society of Korea. Seoul Korea. October 2016.
5

"he effect of a change in reimbursement criteria on the utilization of tumor necrosis factor-alpha inhibitors in elderly patients with rheumatoid arthritis" Youn J, Kim S, and Suh HS , The 2016 Fall International Convention of the Pharmaceutical Society of Korea Seoul, Korea. October 2016.
4

"Combination therapy of BRAF inhibitors for advanced melanoma with V600 BRAF mutation" Kim S, Kim HT, and Suh HS , The 21st International Society for Pharmacoeconomics and Outcomes Research Annual Meeting Washington DC, USA. May 2016.

검색